Review of diphtheria, tetanus and pertussis vaccines in clinical development

References

• Tregnaghi MW, Voelker R, Santos-Lima E, Zambrano B. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant hepatitis B candidate vaccine in healthy adolescents and adults aged 10–45 years. Vaccine28(20), 3595–3601 (2010).
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Zambrano B, Santos-Lima E. Phase I results of an investigational hexavalent DTaP–IPV–Hep B–PRP–T vaccine used as a booster dose in healthy Argentinean 16 to 19 month-old toddlers. Presented at: XIII La Sociedad Latino’a de Infectología Pediátrica (SLIPE). Guayaquil, Ecuador, 12–15 August 2009.
   Google Scholar
• Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr. Infect. Dis. J. DOI: 10.1097/INF.0b013e318212eb80 (2011) (Epub ahead of print).
   Google Scholar
• Macías M, Lanata C, Zambrano B, Santos-Lima E. Safety and immunogenicity of an investigational hexavalent DTaP–IPV–Hep B–PRP–T vaccine at 2, 4, 6 months compared to licensed vaccines in Latin America. Presented at: 6th World Congress of the World Society for Pediatric Infectious Diseases. Buenos Aires, Argentina, 18–22 November 2009.
   Google Scholar
• Madhi SA, Mitha I, Cutland C, Groome M, Santos-Lima E. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatr. Infect. Dis. J.30(4), e68–e74 (2011).
   PubMed Web of Science ®Google Scholar
• Ceyhan C, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent fully liquid DTaP–IPV–Hep B–PRP–T vaccine (Hexaxim™) given at 2, 3, 4 months of age and as a booster at 15–18 months compared to licensed vaccines in Turkish infants. Presented at: 5th Asian Congress of Pediatric Infectious Diseases. Taipei, Taiwan, 23–26 September 2010.
   Google Scholar
• Kosalaraska P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E. Immunogenicity and safety study of a new DTaP–IPV–Hep B–PRP-T combined vaccine compared to a licensed DTaP–IPV–Hep B//PRP–T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int. J. Infect. Dis.15(4), e249–e256 (2011).
   Google Scholar
• Halperin SA, Langley JM, Hesley TM et al. Safety and immunogenicity of two formulations of a hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae conjugate–hepatitis B vaccine in 15 to 18-month-old children. Hum. Vaccin.1(6), 245–250 (2005).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Tapiéro B, Diaz-Mitoma F et al. Safety and immunogenicity of a hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 3, 4, and 12–14 months of age. Vaccine27(19), 2540–2547 (2009).
   PubMed Web of Science ®Google Scholar
• Diaz-Mitoma F, Halperin S, Tapiéro B et al. Safety and immunogenicity of three different formulations of a liquid hexavalent diphtheria–tetanus–acellular pertussis–inactivated poliovirus–Haemophilus influenzae b conjugate–hepatitis B vaccine at 2, 4, 6 and 12–14 months of age. Vaccine29(6), 1324–1331 (2011).
   PubMed Web of Science ®Google Scholar
• Tapiéro B, Halperin S, Dionne M et al. Safety & immunogenicity of a novel hexavalent DTaP–IPV–Hib–HepB vaccine given at 2, 4, and 6 months of age. Presented at: Joint 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Infectious Disease Society of America (IDSA) Meeting. Washington DC, USA, 25–28 October 2008.
   Google Scholar
• Tapiéro B, Halperin S, Dionne M et al. Safety and immunogenicity of a toddler dose of a liquid hexavalent DTaP–IPV–Hib–HepB vaccine following primary series. Presented at: 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Nice, France, 4–8 May 2010.
   Google Scholar
• Tapiéro B, Halperin S, Dionne M et al. Safety & immunogenicity of a hexavalent DTaP5–IPV–Hib–HepB vaccine given at 2, 4,6 and 15 months of age. Presented at: 26th International Pediatric Association Congress of Pediatrics (IPA). Johannesburg, South Africa, 4–9 August 2010.
   Google Scholar
• Knuf M, Schmitt HJ, Wolter J et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J. Pediatr.152(5), 655–660 (2008).
   PubMed Web of Science ®Google Scholar
• Knuf M, Schmitt HJ, Jacquet JM et al. Booster vaccination after neonatal priming with acellular pertussis vaccine. J. Pediatr.156(4), 675–678 (2010).
   PubMed Web of Science ®Google Scholar
• Wood N, McIntyre P, Marshall H, Roberton D. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr. Infect. Dis. J.29(3), 209–215 (2010).
   PubMed Web of Science ®Google Scholar
• Mielcarek N, Debrie AS, Raze D et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog.2(7), e65 (2006).
   PubMed Web of Science ®Google Scholar
• Developing Countries Vaccine Manufacturers Network (DCVMN) Directory 2010.
   Google Scholar
• Zorzeto TQ, Higashi HG, da Silva MT et al. Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants. Clin. Vaccine Immunol.16(4), 544–550 (2009).
   PubMedGoogle Scholar